|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
15,080,000 |
Market
Cap: |
21.87(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.39 - $2.3 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Cumberland Pharmaceuticals is a pharmaceutical company engaged on the acquisition, development and commercialization of prescription products. Co.'s portfolio of brands include: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) for the treatment of constipation; Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori infection and related duodenal ulcer disease; and Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
19,352 |
Total Buy Value |
$0 |
$0 |
$0 |
$46,611 |
Total People Bought |
0 |
0 |
0 |
4 |
Total Buy Transactions |
0 |
0 |
0 |
324 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-04-04 |
2024-01-02 |
2023-07-04 |
2022-07-04 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cearnal Martin E |
Sr VP/Chief Commercial Officer |
|
2021-09-28 |
4 |
AB |
$2.76 |
$290 |
D/D |
105 |
171,459 |
|
28% |
|
Jones James |
Director |
|
2021-09-27 |
4 |
AB |
$2.79 |
$117 |
D/D |
42 |
17,052 |
|
27% |
|
Galante Joseph C |
Director |
|
2021-09-27 |
4 |
AB |
$2.79 |
$396 |
D/D |
142 |
40,369 |
|
27% |
|
Krogulski Kenneth |
Director |
|
2021-09-27 |
4 |
AB |
$2.79 |
$237 |
D/D |
85 |
177,100 |
|
27% |
|
Young Caroline |
Director |
|
2021-09-27 |
4 |
AB |
$2.79 |
$42 |
D/D |
15 |
13,628 |
|
27% |
|
Kazimi A J |
Chairman and CEO |
|
2021-09-27 |
4 |
AB |
$2.79 |
$42 |
D/D |
15 |
5,769,414 |
|
27% |
|
Cearnal Martin E |
Sr VP/Chief Commercial Officer |
|
2021-09-27 |
4 |
AB |
$2.79 |
$293 |
D/D |
105 |
171,354 |
|
27% |
|
Jones James |
Director |
|
2021-09-24 |
4 |
AB |
$2.74 |
$115 |
D/D |
42 |
17,010 |
|
23% |
|
Galante Joseph C |
Director |
|
2021-09-24 |
4 |
AB |
$2.74 |
$389 |
D/D |
142 |
40,227 |
|
23% |
|
Krogulski Kenneth |
Director |
|
2021-09-24 |
4 |
AB |
$2.74 |
$233 |
D/D |
85 |
177,015 |
|
23% |
|
Young Caroline |
Director |
|
2021-09-24 |
4 |
AB |
$2.74 |
$41 |
D/D |
15 |
13,613 |
|
23% |
|
Kazimi A J |
Chairman and CEO |
|
2021-09-24 |
4 |
AB |
$2.74 |
$41 |
D/D |
15 |
5,769,399 |
|
23% |
|
Cearnal Martin E |
Sr VP/Chief Commercial Officer |
|
2021-09-24 |
4 |
AB |
$2.74 |
$288 |
D/D |
105 |
171,249 |
|
23% |
|
Jones James |
Director |
|
2021-09-23 |
4 |
AB |
$2.75 |
$116 |
D/D |
42 |
16,968 |
|
23% |
|
Galante Joseph C |
Director |
|
2021-09-23 |
4 |
AB |
$2.75 |
$391 |
D/D |
142 |
40,085 |
|
23% |
|
Krogulski Kenneth |
Director |
|
2021-09-23 |
4 |
AB |
$2.75 |
$234 |
D/D |
85 |
176,930 |
|
23% |
|
Young Caroline |
Director |
|
2021-09-23 |
4 |
AB |
$2.75 |
$41 |
D/D |
15 |
13,598 |
|
23% |
|
Kazimi A J |
Chairman and CEO |
|
2021-09-23 |
4 |
AB |
$2.75 |
$41 |
D/D |
15 |
5,769,384 |
|
23% |
|
Cearnal Martin E |
Sr VP/Chief Commercial Officer |
|
2021-09-23 |
4 |
AB |
$2.75 |
$289 |
D/D |
105 |
171,144 |
|
23% |
|
Jones James |
Director |
|
2021-09-22 |
4 |
AB |
$2.76 |
$116 |
D/D |
42 |
16,926 |
|
26% |
|
Galante Joseph C |
Director |
|
2021-09-22 |
4 |
AB |
$2.76 |
$392 |
D/D |
142 |
39,943 |
|
26% |
|
Krogulski Kenneth |
Director |
|
2021-09-22 |
4 |
AB |
$2.76 |
$235 |
D/D |
85 |
176,845 |
|
26% |
|
Young Caroline |
Director |
|
2021-09-22 |
4 |
AB |
$2.76 |
$41 |
D/D |
15 |
13,583 |
|
26% |
|
Kazimi A J |
Chairman and CEO |
|
2021-09-22 |
4 |
AB |
$2.76 |
$41 |
D/D |
15 |
5,769,369 |
|
26% |
|
Cearnal Martin E |
Sr VP/Chief Commercial Officer |
|
2021-09-22 |
4 |
AB |
$2.76 |
$290 |
D/D |
105 |
171,039 |
|
26% |
|
2379 Records found
|
|
Page 46 of 96 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|